HS-20124

HS-20124 is a novel antibody-drug conjugate (ADC) of the DAR-8 type that targets Cadherin 6 (CDH6). It was initially developed by Changzhou Humon Pharmaceutical and is currently being developed by Hansoh BioMedical R&D Company. The drug is designed to inhibit tumor cell growth in cancers expressing CDH6, as demonstrated in preclinical studies both in vitro and in vivo. Its mechanism involves targeted delivery of cytotoxic agents to tumor cells via binding to the CDH6 antigen, though the precise payload and linker details are not specified. HS-20124 has entered Phase 1 clinical trials for patients with advanced solid tumors, where its safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity are being evaluated[1][2][3][6].